Latest Intelligence on Biotechnology in Europe

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Xenova/QLT: tackling multidrug resistance

UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.

Published By Datamonitor
11 Jul 2002
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
CommentWire
CommentWire

Virco: looking into the future of AIDS therapy

Published By Datamonitor
17 Jul 2001
CommentWire
CommentWire

Vernalis: revised R&D focus after Frova decision hits home

Vernalis's decision to undergo major restructuring is a direct result of the non-approval of the company's sNDA submission for Frova, for the treatment of menstrual migraine. A successful application had been anticipated to double the revenue potential of Frova.

Published By Datamonitor
22 Feb 2008
CommentWire
CommentWire

Vernalis: Frovelan concerns a headache for shareholders

Published By Datamonitor
20 Sep 2001
CommentWire
CommentWire

Vernalis/Endo: gain in menstrual migraine

New phase III data have confirmed previous results showing Vernalis and Endo's Frova to be an effective preventative treatment for menstrual migraine. This should pave the way for the migraine drug's approval in this additional indication. Anticipated in 2007, this approval is then expected to transform Frova's sales significantly.

Published By Datamonitor
08 May 2006
ResearchWire
ResearchWire

Vaccines: sales show global growth

Published By Datamonitor
17 Mar 2006
CommentWire
CommentWire

Vaccines: Intercell buys Iomai

Intercell has acquired Iomai for $189 million, in a deal motivated by the Austrian company's desire to gain ownership of Iomai's traveler's diarrhea vaccine and transdermal delivery technology. With the potential to deliver both vaccine and adjuvant, independently, through Iomai's transdermal patch, Intercell's development of its proprietary adjuvant IC31 may also benefit from the technology.

Published By Datamonitor
13 May 2008
CommentWire
CommentWire

UK biotechs: biting off more than they can chew

Five non-profitable UK biotech companies may be considering a merger, creating a new cancer player capable of competing against the pharmaceutical majors and of raising the funds needed to create a strong pipeline. But while it seems exciting, the merger could prove a logistical nightmare. A more gradual consolidation effort might suit the biotechs better.

Published By Datamonitor
14 Aug 2002
CommentWire
CommentWire

UK biotech: new heads for the biggest headaches

The UK's biotech leaders - Celltech, CAT, OGS and British Biotech - have all appointed or are about to appoint new CEOs. Not surprising, given the companies' recent poor results both in financial and drug development terms. The changes should signal a shift towards efficient drug development, and a new focus on profitable business development.

Published By Datamonitor
21 Nov 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.